ASCO 2022: Addition of Veliparib to Temozolomide Fails to Improve Survival in Glioblastoma
But survival improvement at intermediate timepoints and following salvage deserves greater scrutiny
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.